Cryoport, Inc. (NASDAQ:CYRX) Shares Sold by Raymond James & Associates

Raymond James & Associates lessened its stake in Cryoport, Inc. (NASDAQ:CYRX) by 19.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,481 shares of the company’s stock after selling 4,260 shares during the quarter. Raymond James & Associates’ holdings in Cryoport were worth $271,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of CYRX. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Cryoport by 13.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company’s stock valued at $157,000 after acquiring an additional 1,395 shares in the last quarter. Advisors Capital Management LLC lifted its stake in shares of Cryoport by 2.5% in the 3rd quarter. Advisors Capital Management LLC now owns 78,993 shares of the company’s stock valued at $1,083,000 after purchasing an additional 1,947 shares during the period. Bullseye Asset Management LLC boosted its holdings in Cryoport by 5.1% during the third quarter. Bullseye Asset Management LLC now owns 133,520 shares of the company’s stock worth $1,831,000 after buying an additional 6,504 shares in the last quarter. Quantbot Technologies LP grew its position in Cryoport by 109.0% during the third quarter. Quantbot Technologies LP now owns 12,838 shares of the company’s stock valued at $176,000 after buying an additional 6,694 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in Cryoport during the third quarter valued at $163,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Price Performance

Shares of Cryoport stock opened at $16.81 on Tuesday. The stock has a market capitalization of $826.38 million, a P/E ratio of -7.64 and a beta of 1.60. The business has a 50 day simple moving average of $16.87 and a two-hundred day simple moving average of $14.99. Cryoport, Inc. has a 12 month low of $9.00 and a 12 month high of $24.17. The company has a debt-to-equity ratio of 0.82, a current ratio of 11.73 and a quick ratio of 11.16.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.19). The firm had revenue of $57.26 million for the quarter, compared to analysts’ expectations of $58.27 million. Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. As a group, analysts predict that Cryoport, Inc. will post -1.31 EPS for the current fiscal year.

Analysts Set New Price Targets

CYRX has been the topic of several recent analyst reports. UBS Group increased their target price on shares of Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a research note on Friday, March 15th. Stephens reiterated an “equal weight” rating and set a $17.00 price target on shares of Cryoport in a research report on Wednesday, March 13th. Needham & Company LLC cut their price objective on Cryoport from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th. Finally, Jefferies Financial Group initiated coverage on Cryoport in a research report on Thursday, April 4th. They set a “buy” rating and a $21.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Cryoport currently has a consensus rating of “Hold” and a consensus price target of $18.63.

Insider Transactions at Cryoport

In related news, CEO Jerrell Shelton sold 2,631 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $17.54, for a total transaction of $46,147.74. Following the transaction, the chief executive officer now directly owns 692,182 shares in the company, valued at $12,140,872.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Cryoport news, Director Ramkumar Mandalam sold 3,217 shares of the business’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $14.68, for a total transaction of $47,225.56. Following the transaction, the director now owns 43,187 shares of the company’s stock, valued at $633,985.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jerrell Shelton sold 2,631 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $17.54, for a total value of $46,147.74. Following the completion of the sale, the chief executive officer now directly owns 692,182 shares of the company’s stock, valued at $12,140,872.28. The disclosure for this sale can be found here. Insiders sold 73,940 shares of company stock valued at $1,147,538 over the last 90 days. 10.10% of the stock is currently owned by corporate insiders.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.